Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Keep vials in their original packaging away from direct light
Impurities in one compound can interact unpredictably with other compounds in a stack, making quality assurance non-negotiable
Reduces discomfort during daily activities
LY3437943 (Retatrutide): discovery to clinical proof of concept (triple GLP-1/GIP/glucagon agonist, preclinical mechanism) Nature Reviews Endocrinology (2024) Multi-receptor agonists for metabolic disease (mechanism of GLP-1/GIP/glucagon co-activation) Diabetes Care (2024) Incretin-based therapies: GLP-1, GIP, and glucagon receptor pharmacology (metabolic pathways, energy expenditure) NEJM (2023) Supplementary Material Jastreboff et al
US$ 26.28
US$ 26.83
US$ 21.07
US$ 24.81
